"Markov Chains" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stochastic process such that the conditional probability distribution for a state at any future instant, given the present state, is unaffected by any additional knowledge of the past history of the system.
| Descriptor ID |
D008390
|
| MeSH Number(s) |
E05.318.740.600.500 E05.318.740.996.500 G17.830.500 N05.715.360.750.625.500 N05.715.360.750.770.500 N06.850.520.830.600.500 N06.850.520.830.996.500
|
| Concept/Terms |
Markov Chains- Markov Chains
- Chains, Markov
- Markov Process
- Markov Processes
- Process, Markov
- Processes, Markov
- Markov Chain
- Chain, Markov
|
Below are MeSH descriptors whose meaning is more general than "Markov Chains".
Below are MeSH descriptors whose meaning is more specific than "Markov Chains".
This graph shows the total number of publications written about "Markov Chains" by people in this website by year, and whether "Markov Chains" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 2 | 2 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Markov Chains" by people in Profiles.
-
Wang CY, Pham PN, Kim S, Lingineni K, Schmidt S, Diaby V, Brown J. Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States. Clin Transl Sci. 2020 03; 13(2):352-361.
-
Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast. 2020 Feb; 49:141-148.
-
Herman PM, Lavelle TA, Sorbero ME, Hurwitz EL, Coulter ID. Are Nonpharmacologic Interventions for Chronic Low Back Pain More Cost Effective Than Usual Care? Proof of Concept Results From a Markov Model. Spine (Phila Pa 1976). 2019 Oct 15; 44(20):1456-1464.
-
Nguyen E, Coleman CI, Kohn CG, Weeda ER. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. Int J Cardiol. 2018 Dec 15; 273:34-38.
-
Okere AN, Ezendu K, Berthe A, Diaby V. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. J Manag Care Spec Pharm. 2018 Feb; 24(2):142-152.
-
Siriwardhana C, Kulasekera KB, Datta S. Flexible semi-parametric regression of state occupational probabilities in a multistate model with right-censored data. Lifetime Data Anal. 2018 07; 24(3):464-491.
-
Sood A, Petersen H, Qualls C, Meek PM, Vazquez-Guillamet R, Celli BR, Tesfaigzi Y. Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. Respir Res. 2016 11 10; 17(1):147.
-
Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016 11; 160(1):187-196.
-
Nguyen E, Egri F, Mearns ES, White CM, Coleman CI. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. Pharmacotherapy. 2016 May; 36(5):488-95.
-
Diaby V, Adunlin G, Zeichner SB, Avancha K, Lopes G, Gluck S, Montero AJ. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):433-41.